Cargando…

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

BACKGROUND: Cangrelor is an intravenous P2Y(12) inhibitor approved to reduce periprocedural ischemic events in patients undergoing percutaneous coronary intervention not pretreated with a P2Y(12) inhibitor. METHODS: A total of 11 145 patients were randomized to cangrelor or clopidogrel in the CHAMPI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cavender, Matthew A., Bhatt, Deepak L., Stone, Gregg W., White, Harvey D., Steg, Ph. Gabriel, Gibson, C. Michael, Hamm, Christian W., Price, Matthew J., Leonardi, Sergio, Prats, Jayne, Deliargyris, Efthymios N., Mahaffey, Kenneth W., Harrington, Robert A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006794/ https://www.ncbi.nlm.nih.gov/pubmed/27482008 http://dx.doi.org/10.1161/CIRCULATIONAHA.115.020829

Ejemplares similares

Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX
por: Cavender, Matthew A., et al.
Publicado: (2021)

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
por: O’Donoghue, Michelle L., et al.
Publicado: (2016)

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
por: Gutierrez, J. Antonio, et al.
Publicado: (2016)

The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX
por: Yong, Celina M., et al.
Publicado: (2019)

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2016)

Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective
por: Jensen, Ivar S., et al.
Publicado: (2021)

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
por: Stone, Gregg W, et al.
Publicado: (2018)

Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
por: De Luca, Leonardo, et al.
Publicado: (2021)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry
por: Selvarajah, Abi, et al.
Publicado: (2021)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry
por: Selvarajah, A., et al.
Publicado: (2021)

Efficacy of Cangrelor as Bridging Therapy Post PCI
por: Khan, Abdul A., et al.
Publicado: (2020)

P2Y(12) Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease
por: Kaza, Elisabeth A., et al.
Publicado: (2017)

Cangrelor Use in Routine Practice: A Two-Center Experience
por: van der Sangen, Niels M. R., et al.
Publicado: (2021)

Cangrelor bridging strategy for liver damage after mechanical chest compression
por: Cereda, Alberto Francesco, et al.
Publicado: (2019)

Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17
por: Luo, Qiancheng, et al.
Publicado: (2021)

Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients
por: Prüller, Florian, et al.
Publicado: (2018)

Safety of Low Dose Intravenous Cangrelor in Acute Ischemic Stroke: A Case Series
por: Salahuddin, Hisham, et al.
Publicado: (2021)

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Urgent Revascularization of the Left Proximal Circumflex Following Cessation of Cangrelor Within Six Hours of Procedure
por: Huang, Sherri, et al.
Publicado: (2023)

Efficacy of a Combined Antiplatelet Therapy Is Not Affected by a Simultaneous Binding of Cangrelor and PSB 0777 to Albumin
por: Wzorek, Joanna, et al.
Publicado: (2021)

Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study
por: Thim, Troels, et al.
Publicado: (2023)

Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus
por: Polak, Dawid, et al.
Publicado: (2021)

The use of cangrelor with heparin for left ventricular assist device implantation in a patient with acute heparin-induced thrombocytopenia
por: Gernhofer, Yan K., et al.
Publicado: (2018)

Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial
por: Gargiulo, Giuseppe, et al.
Publicado: (2020)

Comparison of myocardial reperfusion between intracoronary versus intravenous cangrelor administration in patients undergoing primary percutaneous coronary intervention
por: Muraca, Iacopo, et al.
Publicado: (2023)

Cardioprotective Properties of the Platelet P2Y(12) Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood
por: Bell, R. M., et al.
Publicado: (2015)

Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience
por: Rossini, Roberta, et al.
Publicado: (2020)

Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study
por: De Luca, Leonardo, et al.
Publicado: (2022)

Safety of cangrelor and transition to oral P2Y(12) inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study
por: De Luca, Leonardo, et al.
Publicado: (2023)

Cangrelor Use Patterns and Transition to Oral P2Y(12) Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry
por: Rymer, Jennifer A., et al.
Publicado: (2022)

Cangrelor or Clopidogrel in Patients with Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
por: Lu, Hongtao, et al.
Publicado: (2019)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

High Platelet Reactivity after Transition from Cangrelor to Ticagrelor in Hypothermic Cardiac Arrest Survivors with ST-Segment Elevation Myocardial Infarction
por: Buchtele, Nina, et al.
Publicado: (2020)

Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry
por: Pepe, Martino, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
por: Angiolillo, Dominick J., et al.
Publicado: (2022)

High‐dose IVIG plus cangrelor platelet “anesthesia” during urgent heparin‐CPB in a patient with recent SRA‐negative HIT‐thrombosis with persisting platelet‐activating antibodies
por: Koster, Andreas, et al.
Publicado: (2020)

Safety and Efficacy of Cangrelor Among Three Antiplatelet Regimens During Stent-Assisted Endovascular Treatment of Unruptured Intracranial Aneurysm: A Single-Center Retrospective Study
por: Cheddad El Aouni, Mourad, et al.
Publicado: (2022)

The P2Y(12) Antagonists, 2MeSAMP and Cangrelor, Inhibit Platelet Activation through P2Y(12)/G(i)-Dependent Mechanism
por: Xiang, Binggang, et al.
Publicado: (2012)

Cardioprotecive Properties of Known Agents in Rat Ischemia-Reperfusion Model Under Clinically Relevant Conditions: Only the NAD Precursor Nicotinamide Riboside Reduces Infarct Size in Presence of Fentanyl, Midazolam and Cangrelor, but Not Propofol
por: Xiao, Yang, et al.
Publicado: (2021)

Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation
por: Angiolillo, Dominick J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1ivg8e8erm0599feobn00bp796